Oligonucleotides Archives - Page 2 of 5

OncoWuXi Express: Anti-Tumor mRNA Drugs

OncoWuXi Express will continue to keep you informed about updates to our online tumor model database (OncoWuXi Database), as well...

mRNA-Encoded Modulators Suppress Tumor Growth

Unlike conventional protein-targeted therapies, nucleic acid therapeutics have the potential for long-lasting effects and greater target specificity. WuXi AppTec provides...

Integrated Platform of siRNA Drug Discovery

RNA interference using small interfering RNA (siRNA) molecules has emerged as a promising therapeutic modality. To accelerate the discovery of...

Oligonucleotide Services

Choose excellence, choose WuXi Biology- your reliable partner in oligonucleotide drug discovery. WuXi Biology provides an integrated service platform for...

siRNA Efficacy in a Xenograft Tumor Model

Protein kinase N3 (PKN3) is a serine/threonine kinase implicated in tumor progression across multiple cancer types. PKN3 mRNA is almost undetectable in normal adult...

Rare Disease Therapeutics: Accelerating Development and Improving Access

Advances in the understanding of rare disease biology, coupled with innovative technology and therapeutic platforms, has led to progress in...

OncoWuXi Express: Review of SITC 2023 Annual Meeting

Review of SITC 2023 Annual Meeting The 38th Annual Meeting of the Society for Immunotherapy of Cancer (SITC) was held...

Preclinical platform for nucleic acid drug evaluation: siRNA and mRNA therapeutics

SITC Poster #59: Since the emergence of the COVID-19 pandemic, numerous nucleic-acid therapeutics have been approved for clinical use. Distinguished...

Pioneering Advanced Modalities in Early Drug Discovery

New modalities such as peptides, oligonucleotides, and cell and gene therapies have revolutionized healthcare industry innovation. To meet these evolving...

Knowledge Library